Navigator Medicines
- Biotech or pharma, therapeutic R&D
Navigator Medicines was founded in 2024 and is leading the advancement of biologics for targeted immune regulation and restoration. NAV-240 is a clinical stage bispecific antibody targeting OX40L and TNF-α that is being developed for autoimmune diseases.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}